These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 38869717

  • 21. A decision tree model for predicting intravenous immunoglobulin resistance and coronary artery involvement in Kawasaki disease.
    Joung J, Oh JS, Yoon JM, Ko KO, Yoo GH, Cheon EJ.
    BMC Pediatr; 2022 Aug 05; 22(1):474. PubMed ID: 35931986
    [Abstract] [Full Text] [Related]

  • 22. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
    Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX.
    Zhonghua Er Ke Za Zhi; 2006 Dec 05; 44(12):891-5. PubMed ID: 17254453
    [Abstract] [Full Text] [Related]

  • 23. Inflammatory cytokines as predictors of resistance to intravenous immunoglobulin therapy in Kawasaki disease patients.
    Sato S, Kawashima H, Kashiwagi Y, Hoshika A.
    Int J Rheum Dis; 2013 Apr 05; 16(2):168-72. PubMed ID: 23773640
    [Abstract] [Full Text] [Related]

  • 24. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
    Pediatr Infect Dis J; 2018 Oct 05; 37(10):976-980. PubMed ID: 29461447
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease.
    Wang Y, Wang W, Gong F, Fu S, Zhang Q, Hu J, Qi Y, Xie C, Zhang Y.
    Arthritis Rheum; 2013 Mar 05; 65(3):805-14. PubMed ID: 23440694
    [Abstract] [Full Text] [Related]

  • 26. The combination of the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as a novel predictor of intravenous immunoglobulin resistance in patients with Kawasaki disease: a multicenter study.
    Kanai T, Takeshita S, Kawamura Y, Kinoshita K, Nakatani K, Iwashima S, Takizawa Y, Hirono K, Mori K, Yoshida Y, Nonoyama S.
    Heart Vessels; 2020 Oct 05; 35(10):1463-1472. PubMed ID: 32449049
    [Abstract] [Full Text] [Related]

  • 27. Verification of Current Risk Scores for Kawasaki Disease in Korean Children.
    Shin J, Lee H, Eun L.
    J Korean Med Sci; 2017 Dec 05; 32(12):1991-1996. PubMed ID: 29115081
    [Abstract] [Full Text] [Related]

  • 28. Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin.
    Kibata T, Suzuki Y, Hasegawa S, Matsushige T, Kusuda T, Hoshide M, Takahashi K, Okada S, Wakiguchi H, Moriwake T, Uchida M, Ohbuchi N, Iwai T, Hasegawa M, Ichihara K, Yashiro M, Makino N, Nakamura Y, Ohga S.
    Int J Cardiol; 2016 Jul 01; 214():209-15. PubMed ID: 27070994
    [Abstract] [Full Text] [Related]

  • 29. Kawasaki disease in Turkish children: a single center experience with emphasis on intravenous immunoglobulin resistance and giant coronary aneurysms.
    Yılmazer MM, Özdemir R, Meşe T, Küçük M, Öner T, Devrim İ, Bayram N, Güven B, Tavlı V.
    Turk J Pediatr; 2019 Jul 01; 61(5):648-656. PubMed ID: 32104995
    [Abstract] [Full Text] [Related]

  • 30. Intravenous immunoglobulin for the treatment of Kawasaki disease.
    Broderick C, Kobayashi S, Suto M, Ito S, Kobayashi T.
    Cochrane Database Syst Rev; 2023 Jan 25; 1(1):CD014884. PubMed ID: 36695415
    [Abstract] [Full Text] [Related]

  • 31. Prediction for Intravenous Immunoglobulin Resistance by Using Weighted Genetic Risk Score Identified From Genome-Wide Association Study in Kawasaki Disease.
    Kuo HC, Wong HS, Chang WP, Chen BK, Wu MS, Yang KD, Hsieh KS, Hsu YW, Liu SF, Liu X, Chang WC.
    Circ Cardiovasc Genet; 2017 Oct 25; 10(5):e001625. PubMed ID: 29025760
    [Abstract] [Full Text] [Related]

  • 32. A comparison of the predictive validity of the combination of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and other risk scoring systems for intravenous immunoglobulin (ivig)-resistance in Kawasaki disease.
    Takeshita S, Kanai T, Kawamura Y, Yoshida Y, Nonoyama S.
    PLoS One; 2017 Oct 25; 12(5):e0176957. PubMed ID: 28542183
    [Abstract] [Full Text] [Related]

  • 33. Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease.
    Kimura M, Harazaki M, Fukuoka T, Asakura I, Sakai H, Kamimaki T, Ohkawara I, Akiyama N, Tsurui S, Iwashima S, Shimomura M, Morishita H, Meguro T, Seto S.
    Pediatr Int; 2017 Apr 25; 59(4):397-403. PubMed ID: 27743415
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy.
    Liu J, Ye B, Su D, Qin S, Zhao W, Pang Y.
    Clin Rheumatol; 2023 Jan 25; 42(1):167-177. PubMed ID: 36129563
    [Abstract] [Full Text] [Related]

  • 35. A Retrospective Cohort Study of Intravenous Immunoglobulin Therapy in the Acute Phase of Kawasaki Disease: The Earlier, the Better?
    Li W, He X, Zhang L, Wang Z, Wang Y, Lin H, Yuan J, Xie X, Qin Y, Huang P.
    Cardiovasc Ther; 2021 Jan 25; 2021():6660407. PubMed ID: 34239607
    [Abstract] [Full Text] [Related]

  • 36. N-terminal pro-brain natriuretic peptide (NT proBNP) as a predictive indicator of initial intravenous immunoglobulin treatment failure in children with Kawasaki disease: a retrospective study.
    Kim SY, Han MY, Cha SH, Jeon YB.
    Pediatr Cardiol; 2013 Jan 25; 34(8):1837-43. PubMed ID: 23744100
    [Abstract] [Full Text] [Related]

  • 37. Risk factors of intravenous immunoglobulin resistance and coronary arterial lesions in Turkish children with Kawasaki disease.
    Türkuçar S, Yıldız K, Acarı C, Dundar HA, Kır M, Ünsal E.
    Turk J Pediatr; 2020 Jan 25; 62(1):1-9. PubMed ID: 32253860
    [Abstract] [Full Text] [Related]

  • 38. Prognostic Significance of QT Interval Dispersion in the Response to Intravenous Immunoglobulin Therapy in Kawasaki Disease.
    Motoki N, Akazawa Y, Yamazaki S, Hachiya A, Motoki H, Matsuzaki S, Koike K.
    Circ J; 2017 Mar 24; 81(4):537-542. PubMed ID: 28154289
    [Abstract] [Full Text] [Related]

  • 39. Variability in Response to Intravenous Immunoglobulin in the Treatment of Kawasaki Disease.
    Downie ML, Manlhiot C, Latino GA, Collins TH, Chahal N, Yeung RS, McCrindle BW.
    J Pediatr; 2016 Dec 24; 179():124-130.e1. PubMed ID: 27659027
    [Abstract] [Full Text] [Related]

  • 40. Utility of ferritin as a predictor of the patients with Kawasaki disease refractory to intravenous immunoglobulin therapy.
    Yamamoto N, Sato K, Hoshina T, Kojiro M, Kusuhara K.
    Mod Rheumatol; 2015 Dec 24; 25(6):898-902. PubMed ID: 25849851
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.